UDG Healthcare plc

H1 19: strong cashflow, 5% EPS upgrades on M&A

  • Sectors : Pharma and healthcare
  • Companies : UDG Healthcare plc

Ratings and price correct at time of issue.

  • UDG Healthcare plc

    Closing Price: 655.5p

  • RATING 30/06/09

  • PREVIOUS RATING N/A

DAVY VIEW

UDG has delivered a strong H1 19 performance. We estimate that underlying operating profit rose 6% and FCF conversion was very strong at 77%, putting UDG on track to meet its mid-term cash conversion target this year. In-line with its M&A strategy, it has also announced two deals in the Comms and Advisory space totalling up to $106m spend. We think both are excellent strategic fits. We have left our underlying divisional growth assumptions unchanged and upgrade our FY 2019 and FY 2020 by c.2% and c.5% on today’s deals. This puts the stock on 17.2x 2019 and 15.5x 2020 P/E, with just 0.5x net debt/EBITDA forecast for 2020.

Download full report with analyst certification and important disclosures

May 21 2019, 07:10 IST/BST

Download